Our experiments demonstrated and confirmed a significant increase in frequency of IL-17- and IL-22-secreting Th17 cells in CHC and NAFLD/NASH patients compared to healthy donor [13]–[15] (data not shown). This evidence concerns the gene IL17A and metabolic dysfunction-associated steatohepatitis.